Illumina, Inc. (NASDAQ:ILMN) has seen varied movements in its shareholding structure, with institutions such as
Franklin Resources Inc. and Y Intercept Hong Kong Ltd divesting in the company, while others like
B. Riley Wealth Advisors Inc., Toronto Dominion Bank, Wilmington Savings Fund Society FSB, and others bolstering their positions. The company also disclosed modest gains amid legitimacy approvals and market speculation. Illumina announced its acquisition of
Fluent BioSciences, expanding its single-cell analysis capabilities. Moreover, the company introduced the
MiSeq i100 series, which is claimed to be its simplest and quickest benchtop sequencer. Illumina's board of directors approved the
spin-off of GRAIL, further declaring a spin-off dividend of GRAIL shares. Illumina is also driving the push toward genomics testing becoming a standard in oncology care. However, the company faced some challenges as economic conditions and market forces in China caused scrutiny of Illumina's financial outlook. Corporate developments, including the intended resignation of General Counsel
Charles Dadswell, pose a challenge. Notwithstanding these, the company exceeded earnings expectations while announcing expansions and products such as
DRAGEN v4.3.
Illumina ILMN News Analytics from Mon, 20 May 2024 07:00:00 GMT to Thu, 19 Dec 2024 20:44:55 GMT -
Rating 2
- Innovation 7
- Information 6
- Rumor -4
